Logo

Pacific Biosciences Files $150M Shelf Registration

Nov 07, 2014 | staff reporter

NEW YORK (GenomeWeb) – Pacific Biosciences on Thursday filed a shelf registration to offer up to $150 million of its securities.

According to a document filed with the US Securities and Exchange Commission, the company may offer and sell from time to time shares of its common stock, preferred stock, depositary shares, warrants, debt securities, or units comprising its securities.

PacBio previously filed a $150 million shelf registration in April 2012.

The company had $99.3 million in cash and cash equivalents as of Sept. 30. In the third quarter, PacBio's revenues climbed 178 percent year over year to $20.6 million.

Filed under

Clinical Sequencing
Sequencing
Business News
stock offering
Next-Generation Sequencing
Pacific Biosciences
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.